Skip to main content
Premium Trial:

Request an Annual Quote

Altona Diagnostics Hepatitis C Virus Kit Gets CE-IVD Mark

NEW YORK (GenomeWeb) – Altona Diagnostics said today that it has received CE-IVD marking for and has launched the AltoStar HCV RT-PCR Kit 1.5.

The kit leverages real-time RT-PCR technology to detect and quantify hepatitis C virus-specific RNA with genotypes 1 to 6. The Hamburg, Germany-based company said that the assay is its first List A test, in compliance with the In vitro Diagnostic Directive 98/79/EC.

The assay, which received CE-IVD designation on Wednesday, was developed to be used with Altona's AltoStar Automation System AM16, the AltoStar Purification Kit 1.5, the AltoStar Internal Control 1.5, and Bio-Rad Laboratories' CFX96 Deep Well Real-Time PCR Detection system.

Altona added that additional AltoStar products would soon be available, including tests for hepatitis E virus, hepatitis B virus, and alpha herpesviruses.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.